Common Stock SEC Reporting - Current
Verified Company Profile 6/16/2017
Contact Info
  • 1000 Marina Blvd.
  • Suite 250
  • Brisbane, CA 94005

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0001293310
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2000
Employees Not Available
Company Officers/Contacts
Cameron Durrant CEO
Greg Jester CFO
Morgan Lam CSO
Company Directors
Cameron Durrant Chairman
Ronald Barliant
Dale Chappell
Ezra M. Friedberg
Timothy Morris
Company Notes
  • Formerly=KaloBios Pharmaceuticals, Inc. until 8-2017
  • Note = On December 29, 2015, KaloBios Pharmaceuticals, Inc. filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware(Case No. 15-12628).
Service Providers
Accounting/Auditing Firm
Horne LLP
26 Security Drive
Jackson, TN, 38305
United States

Legal Counsel
Polsinelli PC
100 S. Fourth Street
Suite 1000
St. Louis, MO, 63102
United States

Investor Relations Firm
MZ Group
101 Avenue of the Americas
Suite 411
New York, NY, 10018
United States

HGEN Security Details
Share Structure
Market Value1 $6,251,566 a/o Oct 20, 2017
Authorized Shares 85,000,000 a/o Mar 31, 2017
Outstanding Shares 14,977,397 a/o Mar 31, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 3,800,513 a/o Jun 16, 2017
Par Value Not Available
Transfer Agent(s)
Shareholders of Record 45 a/o Mar 09, 2017
Short Selling Data
Short Interest 2,606 (-84.17%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security